About: Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment
Creator	Mani, Shailendra Bhattacharyya, Sankar Stalin Raj, V Ahmed, Shahbaz Bhasin, Munmun Dutta, Somnath Gayathri, Savitha Girish, Nidhi Joseph, Jeswin Kalita, Parismita Kanjo, Kawkab Kumar Malladi, Sameer Nadig, Gautham Pandey, Suman Pramanick, Ishika Reddy, Poorvi Singh, Ramandeep Singh, Randhir Suhail Khan, Mohammad Thankamani, Karthika Upadhyaya, Aditya Varadarajan, Raghavan
Source	BioRxiv
abstract	Virtually all SARS-CoV-2 vaccines currently in clinical testing are stored in a refrigerated or frozen state prior to use. This is a major impediment to deployment in resource-poor settings. Several use viral vectors or mRNA. In contrast to protein subunit vaccines, there is limited manufacturing expertise for these novel, nucleic acid based modalities, especially in the developing world. Neutralizing antibodies, the clearest known correlate of protection against SARS-CoV-2, are primarily directed against the Receptor Binding Domain (RBD) of the viral spike protein. We describe a monomeric, glycan engineered RBD protein fragment that is expressed at a purified yield of 200mg/L in unoptimized, mammalian cell culture and in contrast to a stabilized spike ectodomain, is tolerant of exposure to temperatures as high as 100°C when lyophilized, and upto 70°C in solution. In prime:boost guinea pig immunizations, when formulated with the MF59 like adjuvant AddaVax™, the RBD derivative elicited neutralizing antibodies with an endpoint geometric mean titer of ~415 against replicative virus, comparing favourably with several vaccine formulations currently in the clinic. These features of high yield, extreme thermotolerance and satisfactory immunogenicity suggest that such RBD subunit vaccine formulations hold great promise to combat COVID-19.
has issue date	2020-08-16(xsd:dateTime)
bibo:doi	10.1101/2020.08.15.252437
has license	biorxiv
sha1sum (hex)	599136b9575d694dc929d583847dfd31e1108f33
schema:url	https://doi.org/10.1101/2020.08.15.252437
resource representing a document's title	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment
schema:publication	bioRxiv
resource representing a document's body	covid:599136b9575d694dc929d583847dfd31e1108f33#body_text
is schema:about of	named entity 'prior' named entity 'protein subunit' named entity 'deployment' named entity 'testing' named entity 'expertise' named entity 'vaccines' named entity 'acid' named entity 'Virtually' named entity 'frozen state' named entity 'viral vectors' named entity 'vaccines' named entity 'protein subunit' named entity 'immunogenic' named entity 'SARS-CoV-2' named entity 'clinical testing' named entity 'virus' named entity 'Pichia' named entity 'SEC' named entity 'infection' named entity 'NTD' named entity 'serum' named entity 'adjuvant' named entity 'RBD' named entity 'pseudotyped' named entity 'protease' named entity 'Vero E6' named entity 'mammalian cell' named entity 'digestion' named entity 'recombinant proteins' named entity 'sodium acetate' named entity 'receptor binding domain' named entity 'PBS' named entity 'Absorbance' named entity 'signal sequence' named entity 'NTD' named entity 'nonspecific binding' named entity 'animal model' named entity 'protein' named entity 'RBD' named entity 'Guinea pigs' named entity 'mRNA' named entity 'vaccination programs' named entity 'Uranyl Acetate' named entity 'adenoviral' named entity 'neutralizing antibodies' named entity 'glycosylation' named entity 'disease susceptibility' named entity 'Protein' named entity 'chromatography' named entity 'pseudovirus' named entity 'protein binding' named entity 'SARS-CoV-2' named entity 'NIH' named entity 'C-termini' named entity 'serum' named entity 'half lives' named entity 'aggregation state' named entity 'viruses' named entity 'ninety minutes' named entity 'Pichia' named entity 'infectious diseases' named entity 'proteolysis' named entity 'immunogenicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software